TNFSF11 and osteoporosis: IL-35 can also be involved in RANKL and M-CSF-induced osteoclasts and angiogenesis via the Th17/IL-17 axis, exhibiting inhibitory effects in both metabolic processes commonly associated with osteoporosis (196), thereby indicating a potential therapeutic direction.